Antibody–drug conjugates: targeted drug delivery for cancerStephen C. Alley, Peter D. Senter, Nicole M. Okeley|Current Opinion in Chemical Biology|2010Cited by 651
Contribution of Linker Stability to the Activities of Anticancer ImmunoconjugatesStephen C. Alley, Peter D. Senter, Dennis R. Benjamin et al.|Bioconjugate Chemistry|2008Cited by 464
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateNicole M. Okeley, Stephen C. Alley, Dennis R. Benjamin et al.|Clinical Cancer Research|2010Cited by 386
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation TechnologyScott C. Jeffrey, Peter D. Senter, Patrick Burke et al.|Bioconjugate Chemistry|2013Cited by 246
Development of orally active inhibitors of protein and cellular fucosylationNicole M. Okeley, Peter D. Senter, Stephen C. Alley et al.|Proceedings of the National Academy of Sciences|2013Cited by 189